BST2 and central nervous system cancer: Functional validation experiments demonstrated that the knockdown of BST2 or DIRAS3 expression in glioma cells significantly suppresses their in vitro migration and invasion capabilities, confirming their critical regulatory roles in malignant phenotypic progression.